Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Astrazeneca PLC (NYSE:AZN) Share Price
Media headlines about Astrazeneca PLC (NYSE:AZN) have trended somewhat positive on Monday, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Astrazeneca PLC earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.6376039431088 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Market Scope: Tracking Shares of Astrazeneca PLC (NYSE:AZN) – Jonesboro Recorder (jonesbororecorder.com)
- ETFs with exposure to AstraZeneca Plc : August 14, 2017 (finance.yahoo.com)
- Investors Buy Large Volume of Astrazeneca PLC Put Options (NYSE:AZN) (americanbankingnews.com)
- Relative Strength Alert For AstraZeneca (nasdaq.com)
- Hot Sentiment Flood at Active Mover: AstraZeneca PLC (AZN) and Weyerhaeuser Co. (WY) – Investing News Update (investingbizz.com)
Astrazeneca PLC (NYSE:AZN) traded up 0.07% on Monday, hitting $29.10. The stock had a trading volume of 2,340,518 shares. Astrazeneca PLC has a 52-week low of $25.55 and a 52-week high of $35.60. The company has a 50-day moving average price of $32.30 and a 200 day moving average price of $31.48. The firm has a market cap of $73.68 billion, a PE ratio of 19.09 and a beta of 0.74.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.46. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The business’s revenue for the quarter was down 9.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.83 EPS. Equities analysts forecast that Astrazeneca PLC will post $1.85 earnings per share for the current fiscal year.
The firm also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a $0.44 dividend. The ex-dividend date is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s payout ratio is 44.92%.
AZN has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Astrazeneca PLC from a “strong-buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub lowered Astrazeneca PLC from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Cowen and Company restated a “hold” rating and set a $34.00 price target on shares of Astrazeneca PLC in a research report on Friday, July 28th. Credit Suisse Group upgraded Astrazeneca PLC from an “underperform” rating to a “neutral” rating in a research report on Friday, May 12th. Finally, Leerink Swann lowered Astrazeneca PLC from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $36.00 to $31.00 in a research report on Thursday, July 27th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $33.39.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.